GlassScriptPhysician profile
Anne Ojala
NPI 1215277611
$2,039.69
in general payments reported to CMS, 2019-2025
20 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $408 · 2023: $473 · 2024: $771 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,208 · Education: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,207.50 |
| Education | $283.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $309.13 | 2023-2024 | Xospata, Cresemba |
| Alexion Pharmaceuticals, INC. | $242.24 | 2023-2024 | Ultomiris, Soliris |
| Janssen Biotech, INC. | $232.64 | 2022-2025 | Talvey, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $159.82 | 2022-2025 | Ojjaara, Blenrep |
| Genzyme Corporation | $125.00 | 2024 | |
| Sobi, INC | $124.79 | 2024 | |
| Sanofi-Aventis U.S. LLC | $119.67 | 2025 | |
| Karyopharm Therapeutics INC. | $115.60 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $114.00 | 2021 | |
| Seagen INC. | $99.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $71.36 | 2023-2024 | |
| Amgen INC. | $68.24 | 2022-2023 | Blincyto |
| Genentech USA, INC. | $57.47 | 2022-2025 | Polivy, Lunsumio, Venclexta |
| Daiichi Sankyo INC. | $56.72 | 2024 | Vanflyta, Injectafer |
| Morphosys, US INC. | $32.02 | 2022-2023 | Monjuvi |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $27.06 | 2021 | |
| Legend Biotech USA INC. | $25.59 | 2024 | |
| Pharmaessentia USA Corporation | $22.73 | 2023 | Besremi |
| Btg International INC. | $19.66 | 2025 | Voraxaze |
| Gamida Cell INC. | $16.95 | 2025 | Omisirge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Ojala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.